<DOC>
	<DOCNO>NCT02579941</DOCNO>
	<brief_summary>Pregnancy induces physiological change hemostasis prothrombotic state : protein S decrease increase virtually clot factor , particular fibrinogen , von Willebrand factor factor VIII . However , state hyperfibrinolysis may occur immediate postpartum period ( especially placental delivery ) , thereby promote postpartum hemorrhage . This state hyperfibrinolysis associate use transfusion blood product realization hysterectomy.It currently common etiology maternal mortality childbirth.There imperative develop efficient reliable protocol management postpartum complication . Tranexamic acid anti-fibrinolytic agent ( like lysine ) act prevent conversion plasminogen plasmin , block bind plasminogen heavy chain fibrin.The optimal dose tranexamic acid enable inhibit fibrinolysis without increase complication rate remains define . It context investigator aim evaluate , in-vitro model , minimum dose tranexamic acid require inhibit fibrinolysis activation latter t-PA . The degree fibrinolysis evaluate thromboelastometry .</brief_summary>
	<brief_title>Evaluation Minimum Concentration Tranexamic Acid Required Inhibit Fibrinolysis Population Pregnant Women Term .</brief_title>
	<detailed_description>Pregnancy induces physiological change hemostasis prothrombotic state : protein S decrease increase virtually clot factor , particular fibrinogen , von Willebrand factor factor VIII . However , state hyperfibrinolysis may occur immediate postpartum period ( especially placental delivery ) , thereby promote postpartum hemorrhage . This state hyperfibrinolysis associate use transfusion blood product realization hysterectomy.It currently common etiology maternal mortality childbirth . Although incidence low western country , remain high world.There imperative develop efficient reliable protocol management postpartum complication . Tranexamic acid anti-fibrinolytic agent ( like lysine ) act prevent conversion plasminogen plasmin , block bind plasminogen heavy chain fibrin.The use agent spread recent year many type surgery ( cardiac , orthopedic , etc . ) , patient polytrauma . However , number study evaluate efficacy management ( treatment / prevention ) postpartum hemorrhage limit . In addition , dos use extrapolated study different population ( multiple trauma , cardiac surgery , etc ) . The tranexamic acid propose scheme currently use suitable population pregnant woman term . It establish arbitrarily basis adult population without consider physiological metabolic characteristic term pregnancy . The optimal dose tranexamic acid enable inhibition fibrinolysis , without increase complication rate , remain thus define . It context investigator aim evaluate , in-vitro model , minimum dose tranexamic acid require inhibit fibrinolysis activation latter t-PA . The degree fibrinolysis evaluate thromboelastometry .</detailed_description>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Pregnant woman group : pregnant woman term ( &gt; 37 week gestation ) patient admit delivery elective cesarian section write informed consent Healthy volunteer group : woman age 18 40 Dying patient ( ASA 5 ) Jehovah 's witness Patients preeclampsia , HELLP syndrome , placenta previa placental abruption . Multiple pregnancy Presence preoperative coagulation disorder define : platelet &lt; 150,000 / mm3 ; PTT &lt; 70 % ; aPTT &gt; 33 sec ; fibrinogen &lt; 350 mg / dL . Treatment anticoagulant antiplatelet agent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Hyperfibrinolysis</keyword>
	<keyword>Pregnant woman term</keyword>
	<keyword>Tranexamic acid</keyword>
</DOC>